November 1, 1991American Journal of HypertensionOpen Access

Cyclic GMP Modulates Release of Norepinephrine From Adrenergic Nerves Innervating Canine Arteries

View Full Paper

Ask AI

Bookmark

Population

Canine arteries (preclinical model)

Comparison

Compounds that stimulate soluble guanylate… vs Compounds that stimulate adenylate cyclase or…

Design

Preclinical

Authors

SGStan S. GreenbergRutgers, The State University of New Jersey ECElinor H. CantorAssociation for Women in Science FDF.P.J. DieckeRutgers, The State University of New Jersey

Discussion

Member takes

Implication

cGMP modulation may inhibit sympathetic activity in vessels; leaves open translation to human hypertension therapy.

Structured PICO

Population

Canine arteries (preclinical model)

Intervention

Compounds that stimulate soluble guanylate cyclase or inhibit cGMP phosphodiesterase

Comparator

Compounds that stimulate adenylate cyclase or inhibit cAMP phosphodiesterase (prostacyclin, papaverine, iloprost, forskolin, rolipram, milrinone, enoximone, piroximone)

Outcome

Sympathetic neurotransmission to vascular smooth muscle and efflux of norepinephrine from sympathetic nervessurrogate

This preclinical study demonstrates that cGMP, but not cAMP, acts as a negative feedback modulator of sympathetic nerve activity to blood vessels.

Cite This Study

Greenberg et al. (1991) studied this question.

synapsesocial.com/papers/6a6ff3b4febe604dd708c4b7 https://doi.org/10.1093/ajh/4.2.173

View Full Paper

Ask AI

Bookmark

Cyclic GMP Modulates Release of Norepinephrine From Adrenergic Nerves Innervating Canine Arteries

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Cyclic GMP Modulates Release of Norepinephrine From Adrenergic Nerves Innervating Canine Arteries

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Also Consider

Also Consider